Cyclerion enters $20M ATM equity distribution agreement with Guggenheim

Cyclerion Therapeutics, Inc.

Entered Sales Agreement with Guggenheim Securities for at-the-market offering of up to $20M of common stock.
Guggenheim will receive 3% commission on gross proceeds; sales limited by public float under Instruction I.B.6.
Company has not sold any securities under Instruction I.B.6 in prior 12 months; current public float below $75M.
Legal opinion from Ropes & Gray covers sale of up to $2,994,080 of Shares under the agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.